As of November 6, 2026, Design Therapeutics, Inc. is a publicly traded company (Nasdaq: DSGN). The largest holder reporting an active stake on Schedule 13D is SR One Capital Fund I Aggregator, LP, at 10.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Sirenia Capital Management LP (9.5%) (Schedule 13D/A, March 11, 2026).
Is this your company?
About to sign with, pay or invest in Design Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Design Therapeutics, Inc. a real, registered company?
- Design Therapeutics, Inc. files with the SEC under CIK 1807120 (its SEC filings).
- Its shares are listed under the ticker DSGN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Carlsbad, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Design Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is David Shapiro, Director (Form 8-K filed 2026-04-01). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Sirenia Capital Management LP (filed 2026-08-14).
Who are Design Therapeutics, Inc.'s owners and officers?
Design Therapeutics, Inc.: incorporated in Delaware; business address in Carlsbad, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Point72 Asset Management, L.P. | 3.8% |
| Schedule 13G, 2026-08-14 | Sirenia Capital Management LP | 9.5% |
| Schedule 13G, 2026-06-09 | Point72 Asset Management, L.P. | 5.1% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 4.4% |
| Schedule 13D/A, 2026-03-11 | Sr One Capital Fund I Aggregator, LP | 10.7% |
| Schedule 13G/A, 2026-02-17 | Point72 Asset Management, L.P. | 9.4% |
| Schedule 13D/A, 2025-11-18 | Logos Global Management LP | 4.4% |
| Schedule 13D/A, 2025-11-12 | Logos Global Management LP | 5.7% |
| Schedule 13G, 2025-08-28 | Point72 Asset Management, L.P. | 5.2% |
Questions about who owns Design Therapeutics, Inc.
Who owns Design Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Design Therapeutics, Inc.: Sr One Capital Fund I Aggregator, LP (10.7%, Schedule 13D/A, filed 2026-03-11) and Sirenia Capital Management LP (9.5%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Design Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Design Therapeutics, Inc. on this page are Sr One Capital Fund I Aggregator, LP (10.7%) and Sirenia Capital Management LP (9.5%).
When did Sr One Capital Fund I Aggregator, LP buy into Design Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Sr One Capital Fund I Aggregator, LP on this page is the Schedule 13D/A, filed 2026-03-11, reporting 10.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Design Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Design Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Design Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-01 | David Shapiro | Director | appointed |
Which insiders own Design Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 3,655,000 shares (5.7% of shares outstanding), held indirectly through By Logos Opportunities Fund II LP and 1 other (Form 4, 2025-08-14).
- , a director: 20,000 shares (0.03% of shares outstanding) (Form 4, 2024-12-19).
Shares outstanding: 64,036,280 as of 2026-10-30, from the company's latest SEC cover page.
How much has Design Therapeutics, Inc. raised?
No fundraising or offering filing from Design Therapeutics, Inc. is on file with us.
Keep reading
More on Design Therapeutics, Inc. and the records around it.
Design Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Apr 2026
Companies that share a holder
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/design-therapeutics